Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model
| Autor: | Emilio Fernández-Espejo, Beatriz Galan-Rodriguez, Fadwa El Banoua, Isabel Caraballo, Juan A. Flores |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: |
Male
Agonist medicine.medical_specialty CB1 antagonism Microinjections medicine.drug_class Globus pallidus D1 receptor Motor Activity Subthalamic nucleus Striatum lcsh:RC321-571 Dopamine receptor D1 Parkinsonian Disorders Piperidines Receptor Cannabinoid CB1 Dopamine receptor D3 Dopamine Internal medicine Dopamine receptor D2 Dopamine receptor D5 Basal ganglia medicine Animals Rats Wistar lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry Receptors Dopamine D2 Chemistry Receptors Dopamine D1 Rats Neostriatum Disease Models Animal Endocrinology Neurology nervous system Dopamine receptor SR141716A Pyrazoles Rimonabant Neuroscience medicine.drug |
| Zdroj: | Neurobiology of Disease, Vol 16, Iss 2, Pp 377-385 (2004) |
| Popis: | Brain cannabinoid CB(1) receptors are expressed in neural areas that contribute to movement such as basal ganglia, where they co-localize with dopamine D(1) and D(2) receptors. The objective of the present study was to further study the functional role of CB(1) receptors along with D(1) and D(2) dopamine receptors of basal ganglia by local injections of SR141716A (CB(1) receptor antagonist), SKF-38393 (D(1) agonist), and quinpirole (D(2) agonist), in a rat Parkinson's model. Turning response after amphetamine was considered as the parkinsonian variable for quantifying motor effects of drugs. The findings indicated that, after intrastriatal infusions, both D(1) or D(2) dopamine receptor agonists alone reduced turning in parkinsonian rats. At the pallidal and subthalamic levels, D(1) (not D(2)) receptor stimulation also reduced rotation. Regarding SR141716A-induced effects, CB(1) antagonism reduced motor asymmetry in parkinsonian rats after injections into striatum, globus pallidus, and to a lesser extent, subthalamic nucleus. At the level of dorsal striatum, effects of SR141716A were mediated through an opposite modulation of D(1) and D(2) dopamine receptor function. At the pallidal and subthalamic nucleus levels, motor effects after SR14716A are not associated to modulation of D(1) and D(2) receptor function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|